Welcome to our dedicated page for Regen Biopharma news (Ticker: RGBP), a resource for investors and traders seeking the latest updates and insights on Regen Biopharma stock.
Regen BioPharma, Inc. (RGBP) generates news primarily around its development of HemaXellerate and its broader immunology and immunotherapy pipeline. Company press releases and third-party research coverage describe Regen BioPharma as a biotechnology issuer focused on autologous cell therapies, RNA and DNA-based therapeutics, RNA vaccines, and small molecule drugs for cancer, autoimmune disorders, and hematological conditions.
A central theme in recent RGBP news is the progression of HemaXellerate, a stem cell-derived, autologous cellular therapy designed to stimulate bone marrow regeneration. Regen BioPharma has announced FDA IND clearance for a planned Phase I clinical trial in aplastic anemia, updates on its Orphan Drug Application for this indication, and plans to present these developments at investor conferences such as the Emerging Growth Conference. Additional releases discuss potential expansion of HemaXellerate into chemotherapy-induced bone marrow suppression and describe its intended multi-lineage regenerative effects on blood cell production.
News items also cover Regen BioPharma’s participation in virtual investor events, where management outlines scientific goals, timelines for moving HemaXellerate into clinical testing, and progress on preclinical programs including mRNA and small molecule therapies. Third-party research reports highlighted in press releases review the company’s transition from preclinical to clinical-stage development, its intellectual property position, and its multiple filed INDs.
Investors following RGBP news can expect updates on regulatory milestones, such as responses to FDA comments on orphan designation, details of planned Phase I trial design, collaborations with clinical research organizations, and historical disclosures about financing activities and share issuances. Bookmarking this page provides a centralized view of Regen BioPharma’s evolving clinical plans, regulatory interactions, and pipeline-related announcements.
Summary not available.
Summary not available.
Summary not available.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) is set to present at the Emerging Growth Conference on February 22, 2023, from 2:40 to 2:50 PM Eastern Time. This live event will provide a platform for interaction with CEO Dr. David Koos, where shareholder questions will be addressed. Key discussion points include updates on a pending reverse stock split and future financing plans. Registration is available for real-time participation and an archived webcast will also be accessible post-event. The conference showcases companies in growth sectors and aims to connect them with investors.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) invites investors to its live presentation at the Emerging Growth Conference on February 8, 2023. The interactive session will provide insights on the company's strategic plans, drug pipeline, and upcoming 1-for-1500 reverse stock split effective March 6, 2023. CEO Dr. David Koos will address shareholder questions during the event.
Regen BioPharma is focused on advancing therapies for cancer and autoimmune disorders through pre-clinical and Phase I/II clinical trials. The conference presentation is scheduled from 2:20 - 2:50 PM Eastern Time. An archived webcast will be available post-event.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on January 25, 2023, from 3:30 - 3:40 PM Eastern. This online event allows shareholders and the investment community to engage with CEO Dr. David Koos in real time. The company aims to update stakeholders on recent intellectual property and respond to questions during the session. Attendees can register for the event at the [official registration link](https://goto.webcasts.com/starthere.jsp?ei=1575092&tp_key=9111d280ed&sti=rgbp). An archived version of the presentation will also be available on [EmergingGrowth.com](http://EmergingGrowth.com).
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) has filed a provisional patent application focused on using survivin-engineered dendritic cells and exosomes to enhance anti-cancer immunity. This approach aims to improve the immune system's ability to target and destroy survivin-expressing tumor cells while sparing healthy tissue. The company draws on prior work with DCellVax for breast cancer treatment and is positioned to diversify its portfolio in the expanding immunotherapy market, which is projected to reach $100 billion globally. CEO David Koos emphasized the potential for new revenue streams through this innovative strategy.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) announced the addition of Dr. Ravinder Reddy and Dr. Mohammad Haris to its Scientific Advisory Board, enhancing its expertise in immunotherapy. Dr. Reddy, a leading researcher in cancer imaging, has over 200 peer-reviewed publications and numerous awards. Dr. Haris specializes in metabolic imaging technologies for cancer and neurological disorders with over 100 publications. CEO David Koos emphasized the importance of their expertise as the company advances its CAR T-cell and immunotherapy initiatives.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) invites investors and analysts to attend its interactive online presentation at the Emerging Growth Conference on November 30, 2022, from 1:45 to 2:00 PM Eastern Time.
The CEO, Dr. David Koos, will provide updates on their CAR T-cell development program and encourage live Q&A participation. If unable to attend, an archived webcast will be available. Regen BioPharma focuses on immunotherapy, advancing mRNA and small molecule therapies for cancer and autoimmune disorders.
Regen BioPharma (OTC PINK: RGBP, RGBPP) is advancing a novel CAR-T therapy, named DuraCAR, designed to treat solid tumors. This innovative approach targets the NR2F6 immune checkpoint, which can suppress T cell activity. By inhibiting NR2F6, DuraCAR aims to prevent T cell exhaustion, enabling enhanced tumor destruction. The company anticipates further experimental results in the coming months to refine this therapeutic approach. Regen BioPharma focuses on immunology and immunotherapy development, striving to address significant challenges in cancer treatment.